NCT00554385 - A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) | Biotech Hunter

Enrollment

283

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

August 31, 2008

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG

ABT-089

Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.

Trial Locations (23)

20170

Site Ref #/Investigator 6835, Herndon

29405

Site Ref #/Investigator 6799, Charleston

32216

Site Ref #/Investigator 6808, Jacksonville

32806

Site Ref #/Investigator 6827, Orlando

34208

Site Ref #/Investigator 8366, Bradenton

38119

Site Ref #/Investigator 7955, Memphis

48085

Site Ref #/Investigator 8428, Troy

53562

Site Ref #/Investigator 6838, Middleton

60048

Site Ref #/Investigator 8383, Libertyville

60062

Site Ref #/Investigator 6802, Northbrook

66212

Site Ref #/Investigator 6824, Overland Park

68198

Site Ref #/Investigator 6902, Omaha

72205

Site Ref #/Investigator 6800, Little Rock

73103

Site Ref #/Investigator 8297, Oklahoma City

78756

Site Ref #/Investigator 6836, Austin

80304

Site Ref #/Investigator 6812, Boulder

89128

Site Ref #/Investigator 6856, Las Vegas

97210

Site Ref #/Investigator 6811, Portland

Site Ref #/Investigator 8701, Portland

97301

Site Ref #/Investigator 6681, Salem

97401

Site Ref #/Investigator 6682, Eugene

98007

Site Ref #/Investigator 6791, Bellevue

08021

Site Ref #/Investigator 6683, Clementon